Dare Bioscience Investor Presentation Deck
OvapreneⓇ
Hormone-Free, Monthly Contraception
Pivotal Phase 3 Study to Commence 2023*
●
Advancing Products Women Want - Late Stage Programs
Sildenafil Cream, 3.6%^
●
B
BAYER
Investigational hormone-free, monthly intravaginal contraceptive.
Designed to be an easy-to-use monthly option with effectiveness approaching hormonal methods. There are currently no
FDA-approved monthly hormone-free contraceptives.
Commercial license agreement with Bayer. Pivotal study collaboration with NICHD.
Female Sexual Arousal Disorder
Phase 2b Study Enrollment to Complete 4Q-2022*
NIH
Investigational cream formulation of sildenafil, the active ingredient in Viagra®, for topical administration to treat FSAD.
FSAD is a physiological condition characterized by the inability to attain or maintain sufficient genital arousal during sexual
activity. There are currently no FDA-approved treatments.
Of the various types of female sexual dysfunction disorders, FSAD is most analogous to erectile dysfunction in men.
Potential first-in-category hormone-
free contraception
Self-administered intravaginal
drug/device
Potential first-in-category treatment
for female sexual arousal disorder
(FSAD)
Topical cream, same active ingredient as
Viagra®
* Anticipated timing
^505(b)(2) regulatory pathway anticipated.
10View entire presentation